Stock CYBN CYBIN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cybin Inc.

Equities

CYBN

CA23256X1006

Market Closed - Nyse
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.3561 USD +2.06% Intraday chart for Cybin Inc. +1.74% -13.15%
May. 06 Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline CI
Apr. 17 Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline
Sector Update: Health Care Stocks Softer Friday Afternoon
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder
Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Cybin reçoit la désignation de thérapie innovante de la FDA pour sa molécule psychédélique CYB003 et annonce des données de durabilité positives à quatre mois pour le traitement du trouble dépressif majeur
Annonce d’un placement privé sursouscrit de 150 millions USD
Cybin erhält von der FDA den Status eines Therapiedurchbruchs für sein neuartiges psychedelisches Molekül CYB003 und gibt positive Daten zur viermonatigen Dauerhaftigkeit bei schwerer depressiver Störung bekannt
Sector Update: Health Care Stocks Ease Wednesday Afternoon
Ankündigung einer überzeichneten Privatplatzierung von 150 Millionen US-Dollar
Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Cybin Gets FDA Clearance for Generalized Anxiety Disorder Study
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
Cybin Inc. Announces Recent Positive Phase 2 CYB003 Topline Results in MDD and Outlines Key Upcoming Milestones Across its Clinical Development Programs
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYBN Stock
  4. News Cybin Inc.
  5. Other languages